Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IlluminaMEX:ILMN -4.53%57 Debt-to-Equity is 0.86 as of Jun. 2026, which is 83% above its 10-year median of 0.47. GuruFocus rates MEX:ILMN with a GF Score™ of 57/100 and a GF Value™ of MXN2,165.86 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, Illumina ranks worse than 80.22% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Illumina's Debt-to-Equity or its related term are showing as below:
MEX:ILMN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.47 Max: 2.03
Current: 0.86
During the past 13 years, the highest Debt-to-Equity Ratio of Illumina was 2.03. The lowest was 0.24. And the median was 0.47.
MEX:ILMN's Debt-to-Equity is ranked worse than 80.22% of 182
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs MEX:ILMN: 0.86
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Illumina Debt-to-Equity Related Terms
Illumina Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Illumina's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ILMN vs MTD, DGX, LH: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Illumina's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Illumina's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (MEX:ILMN) has a Debt-to-Equity of 0.86 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Illumina and its competitors. This is 83% above median its historical median of 0.47. Over the past decade, Illumina's Debt-to-Equity has ranged from 0.24 to 2.03. According to the industry distribution chart, Illumina ranks #146 out of 182 companies in the Medical Diagnostics & Research industry, placing it in the top 80.2%.
Is Illumina's Debt-to-Equity too high?
Illumina's current Debt-to-Equity of 0.86 is 83% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 2.03. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Illumina's value of 0.86 is 160.6% above this industry median. Based on the distribution chart, Illumina ranks #146 out of 182 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Illumina has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Debt-to-Equity compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #146 out of 182 companies for Debt-to-Equity. This places Illumina in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Illumina's value of 0.86 is 160.6% above this benchmark. Historically, Illumina's own Debt-to-Equity has ranged from 0.24 to 2.03 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 0.33, Illumina has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current Debt-to-Equity of 0.86 is 160.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Debt-to-Equity is 0.86, which is 83% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (MEX:ILMN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,165.86, compared to a current price of MXN3,375.00 — trading 55.8% above its estimated fair value. The current Debt-to-Equity is 0.86, which is 83% above median its 10-year median of 0.47 and 160.6% above the Medical Diagnostics & Research industry median of 0.33. Illumina's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Illumina (MEX:ILMN), the current Debt-to-Equity is 0.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (MEX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of MXN3,375.00 is trading 55.8% above its estimated GF Value™ of MXN2,165.86.
GuruFocus considers Illumina to be Significantly Overvalued.
Key valuation signals for MEX:ILMN:
Debt-to-Equity: 0.86 (83% above median its 10-year median of 0.47)
GF Value™: MXN2,165.86 vs. price of MXN3,375.00 (55.8% above fair value)
Industry Position: 160.6% above the Medical Diagnostics & Research median (#146 of 182)
No single metric tells the full story. See the MEX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
57GF Score
Get the complete analysis for MEX:ILMN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ILMN has been successfully added to your 
